Will Cipla set off a sale season?
An investment by a private equity firm or a consortium in the generics maker could set the benchmark for promoters of other pharma companies looking to sell their stake.
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Business
You may also like
Five famous people in our stories this year
From Byju’s Divya Gokulanth to Ebix’s Robin Raina, five personalities that we wrote about in 2024.
Is OYO’s turnaround for real?
Even as the chorus of the company’s turnaround seems to be gathering momentum, it appears that co-founder Ritesh Agarwal’s one-trick pony continues to be financial engineering.
Wockhardt urgently needs Rs 400 crore and its two wonder drugs
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?